T1	AdverseReaction 283 295	Hypoglycemia
T2	DrugClass 1180 1203	GLP-1 receptor agonists
T3	AdverseReaction 1262 1276;1285 1293	thyroid C-cell adenomas
T4	AdverseReaction 1262 1276;1297 1307	thyroid C-cell carcinomas
T5	Animal 1312 1319	rodents
T6	DrugClass 1340 1362	GLP-1 receptor agonist
T7	AdverseReaction 1371 1384	C-cell tumors
T8	Animal 1388 1395	rodents
T9	AdverseReaction 1458 1479	thyroid C-cell tumors
T10	AdverseReaction 1491 1494	MTC
T11	Factor 1427 1434	unknown
T12	AdverseReaction 1630 1633	MTC
T13	AdverseReaction 1794 1797	MTC
T14	DrugClass 1823 1834	liraglutide
T15	AdverseReaction 2013 2016	MTC
T16	DrugClass 2021 2043	GLP-1 receptor agonist
T17	AdverseReaction 3093 3111	acute pancreatitis
T18	AdverseReaction 3230 3242	pancreatitis
T19	AdverseReaction 4135 4147	hypoglycemia
T20	Factor 4127 4131	risk
T21	AdverseReaction 4352 4364	hypoglycemia
T22	Factor 4344 4348	risk
T23	AdverseReaction 4565 4590	hypersensitivity reaction
T24	Severity 4557 4564	serious
T25	AdverseReaction 4596 4604	pruritus
T26	AdverseReaction 4606 4610	rash
T27	AdverseReaction 4616 4623	dyspnea
T28	AdverseReaction 4969 4988	acute renal failure
T29	AdverseReaction 4993 5027	worsening of chronic renal failure
T30	DrugClass 4903 4926	GLP-1 receptor agonists
T31	AdverseReaction 5229 5235	nausea
T32	AdverseReaction 5237 5245	vomiting
T33	AdverseReaction 5247 5255	diarrhea
T34	AdverseReaction 5260 5271	dehydration
T35	AdverseReaction 5385 5411	gastrointestinal reactions
T36	AdverseReaction 5425 5448	renal function declined
T37	AdverseReaction 53 74	Thyroid C-cell Tumors
T38	AdverseReaction 109 121	Pancreatitis
T39	AdverseReaction 479 505	Hypersensitivity Reactions
T40	AdverseReaction 637 653	Renal Impairment
T44	AdverseReaction 1262 1283	thyroid C-cell tumors
E1	AdverseReaction:T1
E2	DrugClass:T2
E3	AdverseReaction:T3 Hypothetical:E2 Hypothetical2:E5
E4	AdverseReaction:T4 Hypothetical:E2 Hypothetical2:E5
E5	Animal:T5
E6	DrugClass:T6
E7	AdverseReaction:T7 Hypothetical:E6 Hypothetical2:E8
E8	Animal:T8
E9	AdverseReaction:T9 Hypothetical:E11
E10	AdverseReaction:T10 Hypothetical:E11
E11	Factor:T11
E12	AdverseReaction:T12
E13	AdverseReaction:T13 Hypothetical:E14
E14	DrugClass:T14
E15	AdverseReaction:T15 Hypothetical:E16
E16	DrugClass:T16
E17	AdverseReaction:T17
E18	AdverseReaction:T18
E19	AdverseReaction:T19 Hypothetical:E20
E20	Factor:T20
E21	AdverseReaction:T21 Hypothetical:E22
E22	Factor:T22
E23	AdverseReaction:T23 Effect:E24
E24	Severity:T24
E25	AdverseReaction:T25
E26	AdverseReaction:T26
E27	AdverseReaction:T27
E28	AdverseReaction:T28 Hypothetical:E30
E29	AdverseReaction:T29 Hypothetical:E30
E30	DrugClass:T30
E31	AdverseReaction:T31
E32	AdverseReaction:T32
E33	AdverseReaction:T33
E34	AdverseReaction:T34
E35	AdverseReaction:T35
E36	AdverseReaction:T36
E37	AdverseReaction:T37
E38	AdverseReaction:T38
E39	AdverseReaction:T39
E40	AdverseReaction:T40
E44	AdverseReaction:T44 Hypothetical:E2 Hypothetical2:E5
A1	CUI E1 C0020615
A2	UMLS-Preferred-Name E1 Hypoglycemia
A3	MEDDRA-PT E1 Hypoglycaemia
A4	MEDDRA-PT-ID E1 10020993
A5	LLT E1 Hypoglycemia
A6	LLT-ID E1 10021005
A7	flag E3 duplicate
A8	CUI E3 C0342190
A9	UMLS-Preferred-Name E3 C-cell hyperplasia of thyroid
A10	MEDDRA-PT E3 Thyroid C-cell hyperplasia
A11	MEDDRA-PT-ID E3 10070568
A12	flag E4 duplicate
A13	CUI E4 C0549473
A14	UMLS-Preferred-Name E4 Thyroid carcinoma
A15	MEDDRA-PT E4 Thyroid cancer
A16	MEDDRA-PT-ID E4 10066474
A17	LLT E4 Thyroid carcinoma
A18	LLT-ID E4 10043702
A19	CUI E7 C1709166
A20	UMLS-Preferred-Name E7 Neoplastic C-Cell Hyperplasia
A21	MEDDRA-PT E7 Thyroid cancer stage 0
A22	MEDDRA-PT-ID E7 10070567
A23	LLT E7 C-cell hyperplasia neoplastic
A24	LLT-ID E7 10070572
A25	flag E9 duplicate
A26	CUI E9 C0342190
A27	UMLS-Preferred-Name E9 C-cell hyperplasia of thyroid
A28	MEDDRA-PT E9 Thyroid C-cell hyperplasia
A29	MEDDRA-PT-ID E9 10070568
A30	CUI E10 C0238462
A31	UMLS-Preferred-Name E10 Medullary carcinoma of thyroid
A32	MEDDRA-PT E10 Medullary thyroid cancer
A33	MEDDRA-PT-ID E10 10027105
A34	LLT E10 Medullary carcinoma of thyroid
A35	LLT-ID E10 10027101
A36	CUI E12 C0238462
A37	UMLS-Preferred-Name E12 Medullary carcinoma of thyroid
A38	MEDDRA-PT E12 Medullary thyroid cancer
A39	MEDDRA-PT-ID E12 10027105
A40	LLT E12 Medullary carcinoma of thyroid
A41	LLT-ID E12 10027101
A42	CUI E13 C0238462
A43	UMLS-Preferred-Name E13 Medullary carcinoma of thyroid
A44	MEDDRA-PT E13 Medullary thyroid cancer
A45	MEDDRA-PT-ID E13 10027105
A46	LLT E13 Medullary carcinoma of thyroid
A47	LLT-ID E13 10027101
A48	CUI E15 C0238462
A49	UMLS-Preferred-Name E15 Medullary carcinoma of thyroid
A50	MEDDRA-PT E15 Medullary thyroid cancer
A51	MEDDRA-PT-ID E15 10027105
A52	LLT E15 Medullary carcinoma of thyroid
A53	LLT-ID E15 10027101
A54	CUI E17 C0001339
A55	UMLS-Preferred-Name E17 Acute pancreatitis
A56	MEDDRA-PT E17 Pancreatitis acute
A57	MEDDRA-PT-ID E17 10033647
A58	LLT E17 Acute pancreatitis
A59	LLT-ID E17 10000971
A60	CUI E18 C0030305
A61	UMLS-Preferred-Name E18 Pancreatitis
A62	MEDDRA-PT E18 Pancreatitis
A63	MEDDRA-PT-ID E18 10033645
A64	CUI E19 C0020615
A65	UMLS-Preferred-Name E19 Hypoglycemia
A66	MEDDRA-PT E19 Hypoglycaemia
A67	MEDDRA-PT-ID E19 10020993
A68	LLT E19 Hypoglycemia
A69	LLT-ID E19 10021005
A70	CUI E21 C0020615
A71	UMLS-Preferred-Name E21 Hypoglycemia
A72	MEDDRA-PT E21 Hypoglycaemia
A73	MEDDRA-PT-ID E21 10020993
A74	LLT E21 Hypoglycemia
A75	LLT-ID E21 10021005
A76	CUI E23 C0020517
A77	UMLS-Preferred-Name E23 Hypersensitivity
A78	MEDDRA-PT E23 Hypersensitivity
A79	MEDDRA-PT-ID E23 10020751
A80	LLT E23 Hypersensitivity reaction
A81	LLT-ID E23 10020756
A82	CUI E25 C0033774
A83	UMLS-Preferred-Name E25 Pruritus
A84	MEDDRA-PT E25 Pruritus
A85	MEDDRA-PT-ID E25 10037087
A86	CUI E26 C0015230
A87	UMLS-Preferred-Name E26 Exanthema
A88	MEDDRA-PT E26 Rash
A89	MEDDRA-PT-ID E26 10037844
A90	CUI E27 C0013404
A91	UMLS-Preferred-Name E27 Dyspnea
A92	MEDDRA-PT E27 Dyspnoea
A93	MEDDRA-PT-ID E27 10013968
A94	LLT E27 Dyspnea
A95	LLT-ID E27 10013963
A96	CUI E28 C0022660
A97	UMLS-Preferred-Name E28 Kidney Failure, Acute
A98	MEDDRA-PT E28 Acute kidney injury
A99	MEDDRA-PT-ID E28 10069339
A100	LLT E28 Acute renal failure
A101	LLT-ID E28 10001041
A102	CUI E29 C0549281
A103	UMLS-Preferred-Name E29 Renal failure chronic aggravated
A104	MEDDRA-PT E29 Chronic kidney disease
A105	MEDDRA-PT-ID E29 10064848
A106	LLT E29 Renal failure chronic aggravated
A107	LLT-ID E29 10038445
A108	CUI E31 C0027497
A109	UMLS-Preferred-Name E31 Nausea
A110	MEDDRA-PT E31 Nausea
A111	MEDDRA-PT-ID E31 10028813
A112	CUI E32 C0042963
A113	UMLS-Preferred-Name E32 Vomiting
A114	MEDDRA-PT E32 Vomiting
A115	MEDDRA-PT-ID E32 10047700
A116	CUI E33 C0011991
A117	UMLS-Preferred-Name E33 Diarrhea
A118	MEDDRA-PT E33 Diarrhoea
A119	MEDDRA-PT-ID E33 10012735
A120	LLT E33 Diarrhea
A121	LLT-ID E33 10012727
A122	CUI E34 C0011175
A123	UMLS-Preferred-Name E34 Dehydration
A124	MEDDRA-PT E34 Dehydration
A125	MEDDRA-PT-ID E34 10012174
A126	CUI E35 C0542184
A127	UMLS-Preferred-Name E35 Reaction gastrointestinal
A128	MEDDRA-PT E35 Gastrointestinal disorder
A129	MEDDRA-PT-ID E35 10017944
A130	LLT E35 Reaction gastrointestinal
A131	LLT-ID E35 10037947
A132	CUI E36 C0232807
A133	UMLS-Preferred-Name E36 Decreased renal function
A134	MEDDRA-PT E36 Renal impairment
A135	MEDDRA-PT-ID E36 10062237
A136	LLT E36 Function kidney decreased
A137	LLT-ID E36 10017474
A138	flag E37 duplicate
A139	CUI E37 C0342190
A140	UMLS-Preferred-Name E37 C-cell hyperplasia of thyroid
A141	MEDDRA-PT E37 Thyroid C-cell hyperplasia
A142	MEDDRA-PT-ID E37 10070568
A143	CUI E38 C0030305
A144	UMLS-Preferred-Name E38 Pancreatitis
A145	MEDDRA-PT E38 Pancreatitis
A146	MEDDRA-PT-ID E38 10033645
A147	CUI E39 C0020517
A148	UMLS-Preferred-Name E39 Hypersensitivity
A149	MEDDRA-PT E39 Hypersensitivity
A150	MEDDRA-PT-ID E39 10020751
A151	LLT E39 Hypersensitivity reaction
A152	LLT-ID E39 10020756
A153	CUI E40 C1565489
A154	UMLS-Preferred-Name E40 Renal Insufficiency
A155	MEDDRA-PT E40 Renal impairment
A156	MEDDRA-PT-ID E40 10062237
A157	flag E44 duplicate
A158	CUI E44 C0342190
A159	UMLS-Preferred-Name E44 C-cell hyperplasia of thyroid
A160	MEDDRA-PT E44 Thyroid C-cell hyperplasia
A161	MEDDRA-PT-ID E44 10070568
